Medicare Covers Prosigna Breast Cancer Recurrence Test
Postmenopausal women with early-stage cancer now have broader access to a genomic test that guides treatment decisions.
Updated on Oct. 16, 2026 in Cancer
Live Poll
Should Medicare prioritize expanding coverage for advanced diagnostic genetic tests?
Medicare began covering the Prosigna breast cancer recurrence test on August 19, 2026. The test provides postmenopausal women with early-stage breast cancer an estimate of their 10-year risk of recurrence to help guide treatment decisions.
Why it matters
This reimbursement decision provides oncologists with a new tool to assess whether chemotherapy is appropriate for specific patients. By accurately estimating long-term risk, clinicians can better tailor treatment plans to avoid unnecessary therapies.
The test's coverage was supported by a technical assessment provided to the MolDX program, which evaluated the assay's ability to analyze tumor biology. It remains to be determined how this standardized coverage will influence long-term patient clinical outcomes in broader practice.
The players
Veracyte
A molecular diagnostics company that develops genomic tests for oncology and other medical specialties.
MolDX
A program managed by Palmetto GBA that assesses molecular diagnostic tests to determine Medicare coverage and reimbursement.
The details
The Prosigna test functions by analyzing tumor biology in combination with clinical and pathological factors to calculate a recurrence risk score. This data helps oncologists determine if the potential benefits of chemotherapy outweigh the risks for individual patients. The test is processed as a laboratory-developed test in San Diego.
Timeline
June 2026: Prosigna launched in the United States.
August 19, 2026: Medicare reimbursement coverage became effective.
October 16, 2026: Veracyte announced the Medicare reimbursement decision.
Health Landscape
This development follows a pattern set by the MolDX program, which vets molecular diagnostics for federal coverage. It represents a shift toward incorporating targeted genomic analysis into standard treatment planning for breast cancer.
Postmenopausal women diagnosed with early-stage ER+ breast cancer may find this test useful for clarifying the potential benefits of chemotherapy. It is worth discussing with your oncologist whether molecular testing is appropriate for your specific stage and lymph node status.
The takeaway
This test provides a targeted look at recurrence risk over a 10-year period to help personalize breast cancer care. Patients should consult their physician about whether this testing is suitable given their specific pathology and treatment goals.
Further reading
For more on evolving standards for tumor testing, see our Cancer coverage.
More information
For clinical details and ordering information, visit the Prosigna clinical resources and ordering portal.
Live Poll
Should Medicare prioritize expanding coverage for advanced diagnostic genetic tests?
